...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Question about Phase 2

The significance of this is that RVX must be getting data on ALP and eGFR for all patients in their Phase 3 trial.  They can see if some are seeing improvements in ALP and eGFR.  As a result, they must have an excellent idea of whether Phase 3 is going as expected.  

My hunch is that they are seeing great results.  Alongwith the 8 safety reviews, we most likely have a block buster drug on our hands.

Share
New Message
Please login to post a reply